Sundry Photography / Shutterstock.com
21 February 2020AmericasRory O'Neill
Gilead fails to have US government patents invalidated
Gilead Sciences has failed in its efforts to have US government patents covering the use of HIV drugs as pre-exposure prophylaxis (PrEP) invalidated.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
22 August 2019 Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.
Americas
2 March 2020 Gilead Sciences has agreed a $4.9 billion deal to buy California-based immuno-oncology company Forty Seven.
Americas
19 May 2020 The US government has urged a Delaware federal court to throw out patent infringement claims from Gilead Sciences over HIV prevention medicines.
Editor's picks
Editor's picks
Americas
22 August 2019 Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.
Americas
2 March 2020 Gilead Sciences has agreed a $4.9 billion deal to buy California-based immuno-oncology company Forty Seven.
Americas
19 May 2020 The US government has urged a Delaware federal court to throw out patent infringement claims from Gilead Sciences over HIV prevention medicines.
Americas
22 August 2019 Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.
Americas
2 March 2020 Gilead Sciences has agreed a $4.9 billion deal to buy California-based immuno-oncology company Forty Seven.
Americas
19 May 2020 The US government has urged a Delaware federal court to throw out patent infringement claims from Gilead Sciences over HIV prevention medicines.